Physician profile
Ramani Dahanayka Yapa
NPI 1699713149
$3,757.16
in general payments reported to CMS, 2019-2025
13 companies · $823 in 2025
The $823 reported for 2025 was more than what 83% of Adolescent Medicine (Internal Medicine) providers received nationally (typical 2025 total: $165).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $418 · 2020: $346 · 2021: $382 · 2022: $310 · 2023: $615 · 2024: $864 · 2025: $823.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,302.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,301.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,720.34 | 2019-2025 | Farxiga, Breztri |
| Lilly USA, LLC | $596.52 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Exact Sciences Corporation | $438.99 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Janssen Pharmaceuticals, INC | $216.56 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $180.02 | 2019-2025 | Jardiance, Tradjenta |
| Novo Nordisk INC | $133.29 | 2020-2025 | Ozempic, Rybelsus |
| Amarin Pharma, INC. | $104.53 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $85.28 | 2021-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $76.46 | 2022-2023 | Xifaxan |
| Pfizer INC. | $71.54 | 2019-2024 | |
| Glaxosmithkline, LLC. | $62.50 | 2023-2024 | Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $47.07 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $24.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramani Yapa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.